Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034637114> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2034637114 abstract "Poly (ADP‐ribose) polymerases (PARP) ‐1 and ‐2 are key enzymes that are activated by DNA damage and play a critical role in the base excision DNA repair (BER) pathway. Previous studies have indicated that inhibitors of PARP‐1 and ‐2 could enhance the efficacy of radiation therapy and chemotherapies by preventing cancer cells from repairing DNA damage. In addition, PARP inhibitors have been shown to selectively kill cancer cells that are deficient in BRCA‐1 or BRCA‐2 function. In this study, we describe the antitumor activity of a series of novel PARP inhibitors in single‐agent therapy and in combination with standard chemotherapies. One of the compounds in this series, LT‐00673, inhibits PARP‐1 with IC50 at sub‐nanomolar (nM) concentration. In cultured human cancer cells, LT‐00673 significantly enhances the cytotoxic efficacy of both Temozolomide and SN‐38 (active metabolite of Irinotecan). LT‐00673 also demonstrates single‐agent cytotoxicity in BRCA‐1 mutant (MX‐1, IC50 = 0.3 nM) and BRCA‐2 mutant cells (Capan‐1, IC50 = 5 nM). In contrast, in MRC‐5 normal human fibroblast and other tumor cell lines with wild‐type BRCA‐1 and BRCA‐2 genes, IC50 of LT‐00673 ranges between 90 nM and 1.9 µM. In rat pharmacokinetic studies, LT‐00673 displays >50% oral bioavailability and pharmacokinetic properties that enable single daily dosing. In xenograft tumor model studies, daily oral dosing of LT‐00673 significantly enhances the antitumor effects of cytotoxic therapies in a dose‐dependent manner. In addition, once daily oral dosing of LT‐00673 at 0.33 mg/kg/day results in complete response in the MX‐1 tumor model. Pharmacodynamic studies have demonstrated potent PARP inhibition by LT‐00673 in tumor biopsies. Off‐target molecular screening did not identify significant non‐specific activity for this class of PARP inhibitors. In summary, LT‐00673 displays potent antitumor activity, along with oral bioavailability and pharmacokinetic properties that support in vivo efficacy on single daily doses, both as single‐agent therapy and in combination with cytotoxic chemotherapies. Conclusion: LT‐00673 shows promising in vitro and in vivo activities and is currently in preclinical development. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A121." @default.
- W2034637114 created "2016-06-24" @default.
- W2034637114 creator A5002012478 @default.
- W2034637114 creator A5022513094 @default.
- W2034637114 creator A5040040696 @default.
- W2034637114 creator A5044112183 @default.
- W2034637114 creator A5073962679 @default.
- W2034637114 creator A5081265349 @default.
- W2034637114 creator A5085037854 @default.
- W2034637114 date "2009-12-10" @default.
- W2034637114 modified "2023-10-11" @default.
- W2034637114 title "Abstract A121: Novel PARP inhibitors with potent antitumor activity as single‐agent and combination therapies" @default.
- W2034637114 doi "https://doi.org/10.1158/1535-7163.targ-09-a121" @default.
- W2034637114 hasPublicationYear "2009" @default.
- W2034637114 type Work @default.
- W2034637114 sameAs 2034637114 @default.
- W2034637114 citedByCount "2" @default.
- W2034637114 countsByYear W20346371142013 @default.
- W2034637114 countsByYear W20346371142015 @default.
- W2034637114 crossrefType "proceedings-article" @default.
- W2034637114 hasAuthorship W2034637114A5002012478 @default.
- W2034637114 hasAuthorship W2034637114A5022513094 @default.
- W2034637114 hasAuthorship W2034637114A5040040696 @default.
- W2034637114 hasAuthorship W2034637114A5044112183 @default.
- W2034637114 hasAuthorship W2034637114A5073962679 @default.
- W2034637114 hasAuthorship W2034637114A5081265349 @default.
- W2034637114 hasAuthorship W2034637114A5085037854 @default.
- W2034637114 hasConcept C109316439 @default.
- W2034637114 hasConcept C121608353 @default.
- W2034637114 hasConcept C126322002 @default.
- W2034637114 hasConcept C134935766 @default.
- W2034637114 hasConcept C154317977 @default.
- W2034637114 hasConcept C181199279 @default.
- W2034637114 hasConcept C182979987 @default.
- W2034637114 hasConcept C185592680 @default.
- W2034637114 hasConcept C202751555 @default.
- W2034637114 hasConcept C2778502085 @default.
- W2034637114 hasConcept C2779138821 @default.
- W2034637114 hasConcept C2779962180 @default.
- W2034637114 hasConcept C502942594 @default.
- W2034637114 hasConcept C552990157 @default.
- W2034637114 hasConcept C55493867 @default.
- W2034637114 hasConcept C71924100 @default.
- W2034637114 hasConcept C82381507 @default.
- W2034637114 hasConcept C96232424 @default.
- W2034637114 hasConcept C98274493 @default.
- W2034637114 hasConceptScore W2034637114C109316439 @default.
- W2034637114 hasConceptScore W2034637114C121608353 @default.
- W2034637114 hasConceptScore W2034637114C126322002 @default.
- W2034637114 hasConceptScore W2034637114C134935766 @default.
- W2034637114 hasConceptScore W2034637114C154317977 @default.
- W2034637114 hasConceptScore W2034637114C181199279 @default.
- W2034637114 hasConceptScore W2034637114C182979987 @default.
- W2034637114 hasConceptScore W2034637114C185592680 @default.
- W2034637114 hasConceptScore W2034637114C202751555 @default.
- W2034637114 hasConceptScore W2034637114C2778502085 @default.
- W2034637114 hasConceptScore W2034637114C2779138821 @default.
- W2034637114 hasConceptScore W2034637114C2779962180 @default.
- W2034637114 hasConceptScore W2034637114C502942594 @default.
- W2034637114 hasConceptScore W2034637114C552990157 @default.
- W2034637114 hasConceptScore W2034637114C55493867 @default.
- W2034637114 hasConceptScore W2034637114C71924100 @default.
- W2034637114 hasConceptScore W2034637114C82381507 @default.
- W2034637114 hasConceptScore W2034637114C96232424 @default.
- W2034637114 hasConceptScore W2034637114C98274493 @default.
- W2034637114 hasLocation W20346371141 @default.
- W2034637114 hasOpenAccess W2034637114 @default.
- W2034637114 hasPrimaryLocation W20346371141 @default.
- W2034637114 hasRelatedWork W2030957604 @default.
- W2034637114 hasRelatedWork W2043297692 @default.
- W2034637114 hasRelatedWork W2093988174 @default.
- W2034637114 hasRelatedWork W2147154862 @default.
- W2034637114 hasRelatedWork W2279794621 @default.
- W2034637114 hasRelatedWork W2286651609 @default.
- W2034637114 hasRelatedWork W2338753295 @default.
- W2034637114 hasRelatedWork W2504216116 @default.
- W2034637114 hasRelatedWork W2551467517 @default.
- W2034637114 hasRelatedWork W2651454156 @default.
- W2034637114 hasRelatedWork W2883524935 @default.
- W2034637114 hasRelatedWork W2886187051 @default.
- W2034637114 hasRelatedWork W2887552575 @default.
- W2034637114 hasRelatedWork W2889230329 @default.
- W2034637114 hasRelatedWork W2913333080 @default.
- W2034637114 hasRelatedWork W3041730055 @default.
- W2034637114 hasRelatedWork W3085495072 @default.
- W2034637114 hasRelatedWork W3134903017 @default.
- W2034637114 hasRelatedWork W3157446121 @default.
- W2034637114 hasRelatedWork W3174662263 @default.
- W2034637114 isParatext "false" @default.
- W2034637114 isRetracted "false" @default.
- W2034637114 magId "2034637114" @default.
- W2034637114 workType "article" @default.